Why Repligen Corporation’s (RGEN) Stock Is Down 5.09%
As of Tuesday, September 01, Repligen Corporation’s RGEN share price has dipped by 5.09%, which has investors questioning if this is right time to buy.Jenna Brashear
Stock Evaluator: Repligen Corporation (RGEN)
Repligen Corporation RGEN
$167.60
-2.01
-1.19%
September 4, 2026 4:00:00 PM
EST
Volume: 806,065
After Hours: $120.37
0.15
|
0.12%
November 10, 2021 7:59 PM
EST
Volume: 72,713
USD
NASD | DELAYED PRICE
| SECTOR | INDUSTRY |
| Health Care | Life Sciences Tools & Services |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally. The company’s products include hollow fiber consumables, KRM chromatography system, resins for new modalities, PATsmart MAVERICK and PATsmart MAVEN for real-time monitoring and control of critical bioprocess parameters, PATsmart REBEL, an at-line cell culture media analyzer; and PATsmart ZipChip, a high-resolution sample separations device, PATsmart SoloVPE slope spectroscopy system, and SoloVPE PLUS System. It offers Protien A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company also provides chromatography products, including OPUS pre-packed chromatography columns, which are used in the purification and quality control of biological drugs, as well as ELISA test kits. In addition, it offers filtration products, such as XCell ATF Cell Retention Systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems. The company offers its products under the OPUS, XCell, XCell ATF, TFDF, KrosFlo, SIUS, ProConnex, Spectra/Por, NGL-Impact, SoloVPE, FlowVPE, RPM, XO, Metenova MixOne, and AVIPure and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has a collaboration agreement with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.
Commentary & Analysis
Which Is a Better Investment, Agilent Technologies, Inc. or Repligen Corporation Stock?
Learn more about whether Agilent Technologies, Inc. or Repligen Corporation is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.Jenna Brashear
Which Is a Better Investment, Danaher Corporation or Repligen Corporation Stock?
Learn more about whether Danaher Corporation or Repligen Corporation is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.Jenna Brashear
Which Is a Better Investment, Illumina, Inc. or Repligen Corporation Stock?
Learn more about whether Illumina, Inc. or Repligen Corporation is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.Tudor Pop
Which Is a Better Investment, IQVIA Holdings Inc. or Repligen Corporation Stock?
Learn more about whether IQVIA Holdings Inc. or Repligen Corporation is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.Michael Rose
Financial Summary
| Share Statistics | RGEN | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $9,458.6 | $3,703.9 | 77% |
|
| Shares Out (Mil) | 56.6 | 98.2 | 50% |
|
| Institutional Ownership | 99.7% | 89.6% | 92% |
|
| Float (Mil) | 53.5 | 71.5 | 48% |
|
| Beta | 1.06 | 1.19 | 64% |
|
| Avg Daily Volume (000s) | 990 | 557 | 72% |
|
| Price Change (52-week) |
39.0% | 85.5% | 76% |
|
| Growth | RGEN | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 15.0% | 7.8% | 73% |
|
| Net Income (5yr) | (4.0%) | (11.2%) | 35% |
|
| EPS (5yr) | (5.0%) | 2.5% | 25 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (24.5%) | (15.0%) | 26% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 17 | 20 | 20 | |
| Current EPS | $0.463 | $2.064 | $2.638 | |
| Month Ago EPS | $0.463 | $2.064 | $2.639 | |
| # Rev Up | 0 | 0 | 0 | |
| # Rev Down | 1 | 1 | 1 | |
| Three Months Ago EPS | $0.474 | $2.002 | $2.546 | |
| Year/Year Chg | 420.2% | 140.0% | 297.0% | |
| Financials | RGEN | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $785 | $810 | 47% |
|
| Net Income (TTM) (Mil) | $42 | ($31) | 53% |
|
| EPS (TTM) | $0.737 | ($0.300) | 57% |
|
| Operating Cash Flow (TTM) (Mil) | $135 | $56 | 55% |
|
| Net Cash Flow (TTM) (Mil) | ($100) | $3 | 14% |
|
| Long-Term Debt (Q1) (Mil) | $672 | $264 | 62% |
|
| Enterprise Value (Q1) (Mil) | $7,985 | $3,795 | 70% |
|
| Valuation | RGEN | Industry Median |
Percentile (All Stocks) |
|
| P/B | 4.48 | 3.74 | 75% |
|
| P/E | 229.6 | 38.8 | 98% |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 5.7 | na |
|
| Ratios | RGEN | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 53.8% | 47.6% | 66% |
|
| Net Margin | 5.3% | (2.6%) | 49% |
|
| ROA | 1.4% | (4.0%) | 51% |
|
| ROE | 2.0% | (7.7%) | 38% |
|
| Liabilities to Assets | 28.4% | 41.1% | 20% |
|
| F-Score | 8 | 5 | 93% |
|
Repligen Corporation did not pass any screens on 9/4/2026.
